Sight Sciences, Inc., (SGHT): Price and Financial Metrics

Sight Sciences, Inc., (SGHT): $4.71

0.22 (+4.90%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

SGHT Price/Volume Stats

Current price $4.71 52-week high $11.20
Prev. close $4.49 52-week low $1.04
Day low $4.44 Volume 86,200
Day high $4.76 Avg. volume 243,066
50-day MA $4.61 Dividend yield N/A
200-day MA $5.12 Market Cap 233.39M

SGHT Stock Price Chart Interactive Chart >

SGHT POWR Grades

  • Sentiment is the dimension where SGHT ranks best; there it ranks ahead of 61.93% of US stocks.
  • SGHT's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • SGHT's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).

SGHT Stock Summary

  • SIGHT SCIENCES INC's stock had its IPO on July 15, 2021, making it an older stock than just 5.71% of US equities in our set.
  • Revenue growth over the past 12 months for SIGHT SCIENCES INC comes in at 26.54%, a number that bests 82.62% of the US stocks we're tracking.
  • In terms of volatility of its share price, SGHT is more volatile than 92.2% of stocks we're observing.
  • Stocks that are quantitatively similar to SGHT, based on their financial statements, market capitalization, and price volatility, are DUOT, STIM, LIQT, ASPN, and WRAP.
  • To check out SIGHT SCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001531177.

SGHT Valuation Summary

  • In comparison to the median Healthcare stock, SGHT's price/earnings ratio is 114.07% lower, now standing at -4.1.
  • SGHT's price/sales ratio has moved down 51.9 over the prior 30 months.

Below are key valuation metrics over time for SGHT.

Stock Date P/S P/B P/E EV/EBIT
SGHT 2023-12-29 3.0 2.0 -4.1 -2.5
SGHT 2023-12-28 3.3 2.1 -4.4 -2.8
SGHT 2023-12-27 3.4 2.2 -4.6 -3.1
SGHT 2023-12-26 3.1 2.0 -4.2 -2.7
SGHT 2023-12-22 2.1 1.4 -2.9 -1.2
SGHT 2023-12-21 1.9 1.2 -2.5 -0.8

SGHT Price Target

For more insight on analysts targets of SGHT, see our SGHT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $43.67 Average Broker Recommendation 1.5 (Moderate Buy)

Sight Sciences, Inc., (SGHT) Company Bio


Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.


SGHT Latest News Stream


Event/Time News Detail
Loading, please wait...

SGHT Latest Social Stream


Loading social stream, please wait...

View Full SGHT Social Stream

Latest SGHT News From Around the Web

Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Decision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patientsMENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their fin

Yahoo | December 28, 2023

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six monthsMENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today an

Yahoo | December 18, 2023

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced t

Yahoo | December 8, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning!

William White on InvestorPlace | December 4, 2023

Independent Chairman of Sight Sciences Picks Up 14% More Stock

Investors who take an interest in Sight Sciences, Inc. ( NASDAQ:SGHT ) should definitely note that the Independent...

Yahoo | November 24, 2023

Read More 'SGHT' Stories Here

SGHT Price Returns

1-mo 14.32%
3-mo 41.44%
6-mo 59.12%
1-year -47.78%
3-year N/A
5-year N/A
YTD -8.72%
2023 -57.74%
2022 -30.51%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!